Adagene (ADAG) news
Recent news
Adagene - To begin phase 1 study of ADG138 for advanced solid tumors in Q4 2026
Adagene Inc. has announced plans to initiate a Phase 1 clinical trial for ADG138, a novel HER2xCD3 POWERbody™, in the fourth quarter of 2026 for the treatment of advanced solid tumors. ADG138 is designed to integrate bispecific T cell engager (TCE) technology with precision masking to mitigate…
AInvest Wire · Sep 22, 2026Adagene - Total potential payments to Adagene under collaboration increased
Adagene Inc. has announced an increase in the total potential payments it could receive under its ongoing collaboration agreement. The updated terms reflect a higher value for the partnership, which includes milestone-based payments and potential royalties related to the development and…
AInvest Wire · Sep 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.